RDHL · RedHill Biopharma Ltd. · Insider Trading
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-10-01 | Raday Gilead |
Chief Operating Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The reporting person sold 1,431 American Depository Shares ("ADS"), of RedHill Biopharma Ltd. (the "Issuer"), each ADS represents 10,000 ordinary shares, which have no par value effective August 7, 2026, solely to satisfy tax withholding obligations incurred upon the vesting of an aggregate of 4,187 Restricted Share Units ("RSU") granted to him on March 26, 2025, and January 23, 2026. Such transaction was effected by the trustee appointed in accordance with the regulations set by the Israeli Tax Authority pursuant to a sell to cover policy and does not represent a discretionary trade by the reporting person. The price reported in Table 1 Column 4 is $0.465 per ADS, which would be equivalent to $0.0000465 per ordinary share. |
Ordinary Shares
|
14,310,000 |
| 2026-10-01 | Raday Gilead |
Chief Operating Officer |
Convert↑
Filing footnotes — American Depository Shares (Direct)
Each ADS is convertible at any time, at the holder's election, for no consideration and has no expiration date. |
American Depository Shares
|
27,560,000 |
| 2026-07-10 | Raday Gilead |
Chief Operating Officer |
Convert↑
Filing footnotes — American Depositary Shares (Direct)
Each ADS is convertible at any time, at the holder's election, for no consideration and has no expiration date. |
American Depositary Shares
|
28,150,000 |
| 2026-07-10 | Raday Gilead |
Chief Operating Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The reporting person sold 1,413 American Depositary Shares ("ADS") of RedHill Biopharma Inc. (the "Issuer"), each ADS represents 10,000 ordinary shares, par value NIS 0.01 per share, solely to satisfy tax withholding obligations incurred upon the vesting of an aggregate of 4,228 restricted share units granted to him on July 1, 2023, June 24, 2024, March 26, 2025 and January 23, 2026. Such transaction was effected by the trustee appointed in accordance with the regulations set by the Israeli Tax Authority pursuant to a sell to cover policy and does not represent a discretionary trade by the reporting person. The price reported in Table I Column 4 is $0.6973 per ADS, which would be equivalent to $0.00006973 per ordinary share. |
Ordinary Shares
|
14,130,000 |
| 2026-04-06 | Raday Gilead |
Chief Operating Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The reporting person sold 1,574 American Depositary Shares ("ADS") of RedHill Biopharma Inc. (the "Issuer"), each ADS represents 10,000 ordinary shares, par value NIS 0.01 per share, solely to satisfy tax withholding obligations incurred upon the vesting of an aggregate of 4,652 restricted share units granted to him on July 1, 2023, June 24, 2024, March 26, 2025 and January 23, 2026. Such transaction was effected by the trustee appointed in accordance with the regulations set by the Israeli Tax Authority pursuant to a sell to cover policy and does not represent a discretionary trade by the reporting person. The price reported in Table I Column 4 is $0.8001 per ADS, which would be equivalent to $0.00008001 per ordinary share. |
Ordinary Shares
|
15,740,000 |
| 2026-04-06 | Raday Gilead |
Chief Operating Officer |
Convert↑
Filing footnotes — American Depositary Shares (Direct)
Each ADS is convertible at any time, at the holder's election, for no consideration and has no expiration date. |
American Depositary Shares
|
30,780,000 |